NORD: Hunter Syndrome (Medical Assistance)

Funded
About
The NORD: Hunter Syndrome (Medical Assistance) program provides crucial support and medical assistance for patients diagnosed with Hunter Syndrome, ensuring access to vital treatments such as Rayos, Tyvaso, Elaprase, and Tyvaso DPI. Designed for uninsured or underinsured U.S. residents, NORD: Hunter Syndrome (Medical Assistance) offers same-day approvals and annual renewals, helping patients efficiently manage their healthcare needs.
Insurance requirements: Underinsured, Uninsured
Enrollment Forms
Enrollment Form
Program Requirements
Valid only for residents in the US and Puerto Rico
Enrollment Required: Yes
Coverage Required: No
Needs Based: Yes
Activation Required: No
Program Details
Please note the following:
1. Program offers medical assistance only
2. Specific drug coverage is not indicated on program website; drug coverage must be verified by calling program
3. Specialty Pharmacy representatives/case managers can send new referrals through the referral portal (https://rareaccess.org/#/login). Representatives must be preregistered by sending a request to RareAccess@rarediseases.org. Representatives can also email the program email address. To make the problem resolution quicker and more efficient please do not send messages to individual emails. If the matter is URGENT, please reach out to SP account manager for NORD to escalate the issue
Patients may apply online, call (2036940412) or email (huntersyndrome@rarediseases.org) program to enroll
Awards are made for a calendar year, and patients may reapply for subsequent years
NORD is able to offer same day approval for programs
Patients must undergo a financial evaluation of need, and provide HIPPA authorization and accept a waiver of liability
Fax number for program is 2033493190
Other Programs
NORD: Hunter Syndrome (Premium & Copay)
Elaprase at no costSee program details for eligibility
NORD: Phenylketonuria (PKU) (Medical Assistance)
Elaprase at no costSee program details for eligibility
Other Tools for Elaprase